In terms of safety, after chemotherapy combined with PD-1 immunotherapy, the most common adverse effects included leukocytopenia and thrombocytopenia; no treatment-related deaths occurred in the two groups. This evidence concerns the gene PDCD1 and Thrombocytopenia.